Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $100.00 price target on Keros Therapeutics (NASDAQ: KROS).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE